292 related articles for article (PubMed ID: 21627339)
1. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
2. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
4. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Porta C
Br J Cancer; 2010 Mar; 102(7):1196-7. PubMed ID: 20179707
[No Abstract] [Full Text] [Related]
5. Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Charbonneau C; Sandin R
Br J Cancer; 2010 Oct; 103(8):1307-8; author reply 1309-10. PubMed ID: 20938457
[No Abstract] [Full Text] [Related]
6. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
10. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
11. Health care costs among renal cancer patients using pazopanib and sunitinib.
Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
[TBL] [Abstract][Full Text] [Related]
14. Update on systemic therapies of metastatic renal cell carcinoma.
Herrmann E; Bierer S; Wülfing C
World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
[TBL] [Abstract][Full Text] [Related]
15. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
17. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
18. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]